Eli Lilly picks up an oral GLP-1 diabetes drug from a big Roche sub for $50M in cash-plus deal — and it’s not a peptide
Eli Lilly has gone shopping for its next GLP-1 diabetes drug at a big Roche subsidiary — and this time we’re not talking about Genentech. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
